36
Radiotherapy Assembled by Norman Reppingen ([email protected] ) Immunity in Cancer

Immunology in radiotherapy

Embed Size (px)

Citation preview

Page 1: Immunology in radiotherapy

Radiotherapy

Assembled by Norman Reppingen ([email protected])

Immunity in Cancer

Page 2: Immunology in radiotherapy

Outline

•The role of immunity in radiotherapy

•A model in a nutshell

•Enabling success

2

Page 3: Immunology in radiotherapy

3

• Immunity in radiotherapy

Page 4: Immunology in radiotherapy

10.1158/0008-5472.CAN-08-0427Kroemer & Zitvogel et al., 2008

Page 5: Immunology in radiotherapy

Outline

• Immunity in radiotherapy

•Dependence on CD8+ cells / DC

•Vaccination / Radiation

5

Page 6: Immunology in radiotherapy

Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation

10.4049/jimmunol.1200563Maries van den Broek et al., 2012

One day before RT (10 Gy), DC or CD8+ cells were depleted.

6

B16gp

Page 7: Immunology in radiotherapy

Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma

10.1016/j.imlet.2006.03.007Min-Geol Lee et al., 2006

Rechallenge resistance:

Ho-166 = ß - Emitter; t1/2 = 26.76 h 7

Page 8: Immunology in radiotherapy

• Cell intrinsic

• Immune mediated

A model in a nutshell

Page 9: Immunology in radiotherapy

A model in a nutshell

10.1016/j.molmed.2013.05.007

Page 10: Immunology in radiotherapy

• Cell intrinsic

10

A model in a nutshell

Page 11: Immunology in radiotherapy

11

Page 12: Immunology in radiotherapy

12

Page 13: Immunology in radiotherapy

13

Page 14: Immunology in radiotherapy

14

Page 15: Immunology in radiotherapy

15

Page 16: Immunology in radiotherapy

16

Page 17: Immunology in radiotherapy

17

Page 18: Immunology in radiotherapy

18

Page 19: Immunology in radiotherapy

19

Page 20: Immunology in radiotherapy

• Immune mediated

A model in a nutshell

Murine mammary carcinoma HE stained, 96 h after 5 Gy of γ irradiation.Stephen L. Shiao & Lisa M. Coussens, 2010

Page 21: Immunology in radiotherapy

21

Page 22: Immunology in radiotherapy

22

Page 23: Immunology in radiotherapy

23

Page 24: Immunology in radiotherapy

24

Page 25: Immunology in radiotherapy

25

Page 26: Immunology in radiotherapy

26

Page 27: Immunology in radiotherapy

Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation

10.4049/jimmunol.1200563Maries van den Broek et al., 2012

One day before RT (10 Gy), DC or CD8+ cells were depleted.

27

B16gp

Page 28: Immunology in radiotherapy

28

10.1016/j.molmed.2013.05.007

Page 29: Immunology in radiotherapy

29

Enabling success

•Breaking Immune Suppression

•TGF-ß & STAT3

•Experiment proposal

Page 30: Immunology in radiotherapy

30

10.1016/j.molmed.2013.05.007

Page 31: Immunology in radiotherapy

31

10.1016/j.molmed.2013.05.007Marco Durante, Norman Reppingen et al., 2013

Inflammatory pathways reassorted

Page 32: Immunology in radiotherapy

Two examples:

•DC therapy & TGF - siRNA at the tumor

•DC therapy with sunitinib

32

Page 33: Immunology in radiotherapy

Gene silencing of TGF-ß1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells

10.1007/s00262-011-1188-yConroy, Mills et al., 2012

DC loaded with hs/irr B16F10 cells and stimulated with CpG (TLR9 Agon.) (3x)siRNA applied to tumor (9x).

Tumors removed on day 21 & stained for CD4, CD8 and analyzed by FACS.

10.1016/j.ccr.2005.10.012

Page 34: Immunology in radiotherapy

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

10.1002/ijc.25863

Sunitinib = STAT3 inhibitor in clinical routine.

MO5 = B16 expressing OVA

Bose & Storkus et al., 2010

Page 35: Immunology in radiotherapy

35

Hypothesis: Antagonizing immune suppressive pathways can turn Radiotherapy into a versatile cancer immune therapy, furnishing quick, cheap and sustainable cure.

10.1016/j.molmed.2013.05.007Marco Durante, Norman Reppingen et al., 2013

Page 36: Immunology in radiotherapy

LiteratureLionel Apetoh et al.: Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res, 68(11):4026–30, 6 2008, 10.1158/0008-5472.CAN-08-0427.

A. Gupta et al.: Radiotherapy promotes tumor-specific effector cd8+ t cells via dendritic cell activation. The Journal of Immunology, 189(2), 558–566, 2012, 10.4049/jimmunol.1200563

Lisa M. Coussens et al.: The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia, 15(4):411–21, 2010, 10.1007/s10911-010-9194-9.

Lee et al.: Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma. Immunology Letters 106 (2006) 19–26, 10.1016/j.imlet.2006.03.007

Mills et al.: Gene silencing of TGF-ß1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells, Cancer Immunol Immunother (2012) 61:425–431; 10.1007/s00262-011-1188-y

Anamika Bose et al.: Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int. J. Cancer: 129, 2158–2170 10.1002/ijc.25863

James W. Hodge et al: Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy, Int. J. Cancer: 130, 1948–1959 (2012), 10.1002/ijc.26219

Marco Durante et al: Immunologically augmented cancer treatment using modern radiotherapy, Trends in Molecular Medicine, 10.1016/j.molmed.2013.05.007

Further Reading & more figures: